Skip to main content

Table 1 Patient demographics and comorbidities for patients with preoperative normal APRI, some liver damage, significant fibrosis, and cirrhosis. Bold p-values indicate statistical significance with pā€‰<ā€‰0.05

From: The role of preoperative aspartate aminotransferase-to-platelet ratio index in predicting complications following total hip arthroplasty

Ā 

Normal (ā‰¤ā€‰0.5)

Some liver damage (0.5ā€“0.7)

Significant fibrosis (0.7ā€“1)

Cirrhosis (ā‰„ā€‰1)

Number (%)

Number (%)

p-value

Number (%)

p-value

Number (%)

p-value

Overall

103,678

444

Ā 

256

Ā 

253

Ā 

Sex

Ā Ā 

ā€‰<ā€‰0.001

Ā 

ā€‰<ā€‰0.001

Ā 

0.004

ā€ƒFemale

57,004 (55.0)

194 (43.7)

Ā 

105 (41.0)

Ā 

116 (45.8)

Ā 

ā€ƒMale

46,674 (45.0)

250 (56.3)

Ā 

151 (59.0)

Ā 

137 (54.2)

Ā 

Age

Ā Ā 

ā€‰<ā€‰0.001

Ā 

ā€‰<ā€‰0.001

Ā 

ā€‰<ā€‰0.001

ā€ƒ18ā€“39

2,164 (2.1)

12 (2.7)

Ā 

7 (2.7)

Ā 

8 (3.2)

Ā 

ā€ƒ40ā€“64

44,341 (42.8)

254 (57.3)

Ā 

159 (62.4)

Ā 

147 (58.1)

Ā 

ā€ƒ65ā€“74

34,941 (33.7)

114 (25.7)

Ā 

56 (22.0)

Ā 

61 (24.1)

Ā 

ā€ƒā€‰ā‰„ā€‰75

22,134 (21.4)

63 (14.2)

Ā 

33 (12.9)

Ā 

37 (14.6)

Ā 

BMI (kg/m^2)

Ā Ā 

0.031

Ā 

0.176

Ā 

0.002

ā€ƒā€‰<ā€‰18.5

985 (1.0)

8 (1.8)

Ā 

3 (1.2)

Ā 

3 (1.2)

Ā 

ā€ƒ18.5ā€“29.9

19,443 (18.8)

100 (22.5)

Ā 

60 (23.4)

Ā 

72 (28.5)

Ā 

ā€ƒ30ā€“34.9

33,962 (32.8)

123 (27.7)

Ā 

89 (34.8)

Ā 

80 (31.6)

Ā 

ā€ƒ35ā€“39.9

41,564 (40.1)

176 (39.6)

Ā 

90 (35.2)

Ā 

84 (33.2)

Ā 

ā€ƒā€‰ā‰„ā€‰40

7,726 (7.5)

37 (8.3)

Ā 

14 (5.5)

Ā 

14 (5.5)

Ā 

Functional Status Prior to Surgery

Ā Ā 

0.865

Ā 

ā€‰<ā€‰0.001

Ā 

0.120

ā€ƒDependent

2,222 (2.1)

9 (2.0)

Ā 

17 (6.7)

Ā 

9 (3.6)

Ā 

ā€ƒIndependent

101,181 (97.9)

434 (98.0)

Ā 

237 (93.3)

Ā 

243 (96.4)

Ā 

Frailty

Ā Ā 

0.923

Ā 

0.457

Ā 

0.813

ā€ƒā€‰<ā€‰2

102,223 (98.6)

438 (98.6)

Ā 

251 (98.0)

Ā 

249 (98.4)

Ā 

ā€ƒā€‰ā‰„ā€‰2

1,457 (1.4)

6 (1.4)

Ā 

5 (2.0)

Ā 

4 (1.6)

Ā 

ASA classification

Ā Ā 

ā€‰<ā€‰0.001

Ā 

0.004

Ā 

ā€‰<ā€‰0.001

ā€ƒā€‰ā‰¤ā€‰2

54,372 (52.4)

165 (37.2)

Ā 

111 (43.4)

Ā 

83 (32.8)

Ā 

ā€ƒā€‰ā‰„ā€‰3

49,308 (47.6)

279 (62.8)

Ā 

145 (56.6)

Ā 

170 (67.2)

Ā 

Smoker

Ā Ā 

ā€‰<ā€‰0.001

Ā 

ā€‰<ā€‰0.001

Ā 

ā€‰<ā€‰0.001

ā€ƒNo

90,397 (87.2)

344 (77.5)

Ā 

186 (72.7)

Ā 

190 (75.1)

Ā 

ā€ƒYes

13,283 (12.8)

100 (22.5)

Ā 

70 (27.3)

Ā 

63 (24.9)

Ā 

Steroid use

Ā Ā 

0.829

Ā 

0.392

Ā 

0.564

ā€ƒNo

98,784 (95.3)

424 (95.5)

Ā 

241 (94.1)

Ā 

243 (96.0)

Ā 

ā€ƒYes

4,896 (4.7)

20 (4.5)

Ā 

15 (5.9)

Ā 

10 (4.0)

Ā 

Comorbidities

ā€ƒHTN

60,670 (58.5)

269 (60.6)

0.385

138 (53.9)

0.144

144 (56.9)

0.606

ā€ƒCHF

536 (0.5)

4 (0.9)

0.299

2 (0.8)

0.382

1 (0.4)

1.000

ā€ƒDiabetes Mellitus

13,968 (13.5)

75 (16.9)

0.035

43 (16.8)

0.120

37 (14.6)

0.592

ā€ƒCOPD

4,634 (4.5)

25 (5.6)

0.238

12 (4.7)

0.879

14 (5.5)

0.363

ā€ƒBleeding Disorder

2,701 (2.6)

58 (13.1)

ā€‰<ā€‰0.001

34 (13.3)

ā€‰<ā€‰0.001

42 (16.6)

ā€‰<ā€‰0.001

  1. APRI AST to Platelet Ratio Index, BMI body mass index, ASA American Society of Anesthesiologists, CHF congestive heart failure, COPD chronic obstructive pulmonary disease